Status:

RECRUITING

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Glioma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This trial uses magnetic resonance elastography (MRE) to estimate tissue stiffness (hardness or softness of the tissue) in tissue that is affected by radiation treatment (radiation necrosis) and tumor...

Detailed Description

PRIMARY OBJECTIVES: I. To estimate the mean lesion stiffness in patients with radiation necrosis using magnetic resonance elastography (MRE). II. To estimate the mean lesion stiffness in patients wi...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • \>/=18 years old.
  • History of a pathology proven intracranial glioma (including IDH mutant, IDH wildtype or 1p19q co-deleted tumors) treated with chemotherapy and radiation.
  • The lesion of concern (T2 Flair Hyperintense or contrast enhancing lesion) is \> 2 cm
  • Patient is able to understand and give consent to participation in the study.
  • Exclusion Criteria
  • Patients less than 18 years of age.
  • Pregnant.
  • Known allergy to gadolinium-based contrast agents.
  • Renal failure as evidenced by a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m2.
  • Pacemakers, electronic stimulation, metallic foreign bodies and devices and/or other conditions that are not MR safe, which include but are not limited to:
  • electronically, magnetically, and mechanically activated implants
  • ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers
  • metallic splinters in the eye
  • ferromagnetic hemostatic clips in the central nervous system (CNS) or body
  • cochlear implants
  • other pacemakers, e.g., for the carotid sinus
  • insulin pumps and nerve stimulators
  • non-MR safe lead wires
  • prosthetic heart valves (if dehiscence is suspected)
  • non-ferromagnetic stapedial implants
  • claustrophobia that does not readily respond to oral medication

Exclusion

    Key Trial Info

    Start Date :

    March 20 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    November 1 2028

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT04373720

    Start Date

    March 20 2020

    End Date

    November 1 2028

    Last Update

    September 5 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    M D Anderson Cancer Center

    Houston, Texas, United States, 77030